Elevated FSH has been detected in postmenopausal women, suggesting it negatively impacts BMD (Wang et al. 2015) and it was proposed that FSH contributes to postmenopausal osteoporosis by stimulating osteoclast differentiation (Wang et al. 2015) through the FSH receptor (FSHR) expressed on osteoclast precursors and mature osteoclasts (Chin 2018). This evidence concerns the gene BRD2 and postmenopausal osteoporosis.